Sight Sciences, Inc. (SGHT)

Market Cap	527.19M +94.7%
Revenue (ttm)	83.38M +9.3%
Net Income	-29.76M
EPS	-0.56
Shares Out	55.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	346,456
Open	9.25
Previous Close	9.24
Day's Range	9.25 - 9.63
52-Week Range	3.38 - 9.71
Beta	2.45
Analysts	Buy
Price Target	10.17 (+6.27%)
Earnings Date	Nov 4, 2026

About SGHT

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and O...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 186
• Stock Exchange: Nasdaq
• Ticker Symbol: SGHT
• Website: https://www.sightsciences.com

Financial Performance

In 2025, Sight Sciences's revenue was $77.36 million, a decrease of -3.13% compared to the previous year's $79.87 million. Losses were -$38.43 million, -25.40% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price target is $10.17, which is an increase of 6.27% from the latest price.

Price Target

$10.17

(6.27% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 30, 2026

Data Sources Report a data error